These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 18331562

  • 1. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.
    HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz-Fernández A, Spanish Group of Paediatric HIV Infection.
    Clin Infect Dis; 2006 Mar 15; 42(6):862-9. PubMed ID: 16477566
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 4. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
    Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C.
    HIV Med; 2008 Oct 13; 9(9):738-46. PubMed ID: 18651858
    [Abstract] [Full Text] [Related]

  • 5. A prospective study of haematological changes after switching from stavudine to zidovudine-based antiretroviral treatment in HIV-infected children.
    Singh A, Hemal A, Agarwal S, Dubey NK, Buxi G.
    Int J STD AIDS; 2016 Nov 13; 27(13):1145-1152. PubMed ID: 24516076
    [Abstract] [Full Text] [Related]

  • 6. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 15; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 8. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.
    AIDS; 2008 Sep 12; 22(14):1815-20. PubMed ID: 18753864
    [Abstract] [Full Text] [Related]

  • 9. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    Antivir Ther; 2005 Sep 12; 10(2):335-41. PubMed ID: 15865228
    [Abstract] [Full Text] [Related]

  • 10. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
    Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S.
    Pediatrics; 1995 Aug 12; 96(2 Pt 1):247-52. PubMed ID: 7630678
    [Abstract] [Full Text] [Related]

  • 11. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattré P, Mouton Y.
    J Antimicrob Chemother; 2004 Jan 12; 53(1):89-94. PubMed ID: 14645320
    [Abstract] [Full Text] [Related]

  • 12. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.
    AIDS; 2007 May 11; 21(8):939-46. PubMed ID: 17457087
    [Abstract] [Full Text] [Related]

  • 13. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.
    Antivir Ther; 2007 May 11; 12(3):407-15. PubMed ID: 17591031
    [Abstract] [Full Text] [Related]

  • 14. Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.
    Byakwaga H, Zhou J, Petoumenos K, Law MG, Boyd MA, Emery S, Cooper DA, Mallon PW.
    HIV Med; 2009 Mar 11; 10(3):143-51. PubMed ID: 19207595
    [Abstract] [Full Text] [Related]

  • 15. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy.
    Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F.
    HIV Med; 2007 Nov 11; 8(8):483-90. PubMed ID: 17944680
    [Abstract] [Full Text] [Related]

  • 16. Hematologic changes associated with Zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda.
    Forna F, Moore D, Mermin J, Brooks JT, Were W, Buchacz K, Campbell JD, Downing R, Borkowf CB, Weidle PJ.
    J Int Assoc Physicians AIDS Care (Chic); 2009 Nov 11; 8(2):128-38. PubMed ID: 19270152
    [Abstract] [Full Text] [Related]

  • 17. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, Médecins Sans Frontieres.
    AIDS; 2006 May 12; 20(8):1163-9. PubMed ID: 16691068
    [Abstract] [Full Text] [Related]

  • 18. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.
    J Infect Dis; 2009 Nov 15; 200(10):1490-7. PubMed ID: 19832114
    [Abstract] [Full Text] [Related]

  • 19. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 20. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F.
    HIV Med; 2006 Oct 17; 7(7):431-6. PubMed ID: 16925728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.